The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity

Haghani, Masoud; Shabani, Mohammad; Tondar, Mahdi

doi:10.1016/j.ejphar.2015.03.016

Cited by 52 publications

(43 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… MWM, Elevated plus maze task, LDH: Labtest kit, AChE activity Patil et al [ 21 ] 200–250 g memory-impairment Wistar rats model induced by ethanol (male,12) 25, 50 and 100 mg/kg berberine, vitamin C (100 mg/kg), and vehicle (1 mL/kg), DDW control rats(double distilled water), orally administration (chronic treatment: once a day for 45 days before training; acute treatment: once a day for 5 days during training). MWM, Memory consolidation test, Elevated plus maze test, ChE activity Haghani et al [ 22 ] 200–250 g 60–65 days Aβ infused Wistar rats model (male, 32) Sham(normal saline), berberine(50 mg/kg), Aβ(normal saline)and Aβ + berberine(berberine 50 mg/kg) ( n = 8 rats in each group), intraperitoneal administration daily for 13 days. MWM, Passive avoidance test, Zhan et al [ 23 ] 180–220 g, 10–12 weeks D-galactose-induced memory impairment Wistar rats (male) Berberine (100 mg/kg per day), orally administration for 7 weeks.…”

Section: Resultsmentioning

confidence: 99%

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Yuan

Cai

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

Background Berberine is an isoquinoline alkaloid extracted from various Berberis species which is widely used in East Asia for a wide range of symptoms. Recently, neuroprotective effects of berberine in Alzheimer’s disease (AD) animal models are being extensively reported. So far, no clinical trial has been carried out on the neuroprotective effects of berberine. However, a review of the experimental data is needed before choosing berberine as a candidate drug for clinical experiments. We conducted a systematic review on AD rodent models to analyze the drug effects with minimal selection bias. Methods Five online literature databases were searched to find publications reporting studies of the effect of berberine treatment on animal models of AD. Up to March 2018, 15 papers were identified to describe the efficacy of berberine. Results The included 15 articles met our inclusion criteria with different quality ranging from 3 to 5. We analyzed data extracted from full texts with regard to pharmacological effects and potential anti-Alzheimer’s properties. Our analysis revealed that in multiple memory defects animal models, berberine showed significant memory-improving activities with multiple mechanisms, such as anti-inflammation, anti-oxidative stress, cholinesterase (ChE) inhibition and anti-amyloid effects. Conclusion AD is likely to be a complex disease driven by multiple factors. Yet, many therapeutic strategies based on lowering β-amyloid have failed in clinical trials. This suggest that the threapy should not base on a single cause of Alzheimer’s disease but rather a number of different pathways that lead to the disease. Overall we think that berberine can be a promising multipotent agent to combat Alzheimer’s disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Yuan

Cai

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, BBR protects against ischemia damage through blockades on transient outward potassium current (IA) and delayed rectifier potassium current (IK) are preferential for IK and in a concentration‐dependent manner in acutely isolated CA1 pyramidal neurons of rat hippocampus (F. Wang et al, ). BBR can also modulated IA in the CA1 pyramidal neurons to improve their frequency and excitability (Haghani, Shabani, & Tondar, ). Tetrahydroberberine also blocks K(ATP) channels in dopaminergic neurons dissociated from the substantia nigra pars compacta in rat, which exhibits an excitatory effect on neurons and promote PD pathogenesis (C. Wu et al, ).…”

Section: Other Neuroprotective Pathwaysmentioning

confidence: 99%

Section: K + Currentsmentioning

confidence: 99%

Berberine: Pathways to protect neurons

Lin

Zhang

2018

Phytotherapy Research

View full text Add to dashboard Cite

Berberine, an isoquinoline alkaloid, is demonstrated to have a variety of pharmacologic effects. Widely used as nonprescription drug for diarrhea, berberine has also broadened its applications in therapies of cardiovascular diseases, diabetes mellitus, tumor, and so forth. However, researches about berberine's protective effects on nervous system are still so insufficient that clinical uses cannot popularize and underlying molecules mechanisms are confused and incomplete. Well-known pathways such as Pl3K/Akt/Bcl-2 pathway, Nrf2/HO-1 pathway, and MAPK signaling pathway help berberine to protect neurons through antiapoptotic, antioxidative, and anti-inflammatory activities. New hypotheses have been raised consistently to explore more possible ways of berberine preventing nerves from injuries as attention on its neuroprotective properties is increasing. Therefore, this review is trying to analyze these mechanisms, which actually play roles in neuronal disease models such as brain ischemia, Alzheimer's disease, and experimental autoimmune encephalomyelitis. Much more understanding about how berberine mediates these pathways provides novel insights into the clinical treatment of neurological disorders.

show abstract

“…Recent studies suggested that the neurobiological effects of berberine may contribute to clinical benefits for AD by decreasing the generation of Aβ 61 , 62 ( Figure 1 ). An in vitro study demonstrated that berberine inhibited Aβ-stimulated production of interleukin-6 and monocyte chemotactic protein-1 and downregulated the expression of cyclo-oxygenase-2 and induced nitric oxide synthase by blocking the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase signaling pathways in primary microglial and BV2 cells.…”

Section: Berberine and Beta-amyloid Pathologymentioning

confidence: 99%

Role of berberine in Alzheimer’s disease

Cai

Wang

Yang

2016

NDT

124

View full text Add to dashboard Cite

Berberine, an important protoberberine isoquinoline alkaloid, has several pharmacological activities, including antimicrobial, glucose- and cholesterol-lowering, antitumoral, and immunomodulatory properties. Substantial studies suggest that berberine may be beneficial to Alzheimer’s disease (AD) by limiting the pathogenesis of extracellular amyloid plaques and intracellular neurofibrillary tangles. Increasing evidence has indicated that berberine exerts a protective role in atherosclerosis related to lipid- and glucose-lowering properties, implicating that berberine has the potential to inhibit these risk factors for AD. This review also attempts to discuss the pharmacological basis through which berberine may retard oxidative stress and neuroinflammation to exhibit its protective role in AD. Accordingly, berberine might be considered a potential therapeutic approach to prevent or delay the process of AD. However, more detailed investigations along with a safety assessment of berberine are warranted to clarify the role of berberine in limiting these risk factors and AD-related pathologies.

show abstract

The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity

Cited by 52 publications

References 36 publications

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Berberine: Pathways to protect neurons

Role of berberine in Alzheimer’s disease

Contact Info

Product

Resources

About

The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity

Cited by 52 publications

References 36 publications

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies

Berberine: Pathways to protect neurons

Role of berberine in Alzheimer&rsquo;s disease

Contact Info

Product

Resources

About

Role of berberine in Alzheimer’s disease